Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICAD Stock Forecast 2025-2026
$3.87
Current Price
$106.31M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to ICAD Price Targets
+3.4%
To High Target of $4.00
-3.1%
To Median Target of $3.75
-9.6%
To Low Target of $3.50
ICAD Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+122.4%
1 Year Change
+111.5%
Year-to-Date Change
-3.5%
From 52W High of $4.01
+225.2%
From 52W Low of $1.19
📊 TOP ANALYST CALLS
Did ICAD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Icad Inc is one of their latest high-conviction picks.
Latest ICAD Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ICAD has a neutral consensus with a median price target of $3.75 (ranging from $3.50 to $4.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.87, the median forecast implies a -3.1% downside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 3.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICAD Analyst Ratings
0
Buy
4
Hold
0
Sell
ICAD Price Target Range
Low
$3.50
Average
$3.75
High
$4.00
Current: $3.87
Latest ICAD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICAD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Laidlaw & Co. | Yale Jen | Hold | Downgrade | $N/A |
| Jul 19, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $5.00 |
| Apr 13, 2023 | JMP Securities | David Turkaly | Outperform | Maintains | $4.00 |
| Apr 4, 2023 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $4.00 |
| Mar 29, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $2.50 |
| Mar 29, 2023 | BTIG | Marie Thibault | Buy | Maintains | $3.00 |
| Sep 1, 2022 | JMP Securities | David Turkaly | Market Outperform | Maintains | $7.00 |
| Aug 11, 2022 | Lake Street | Frank Takkinen | Buy | Maintains | $8.00 |
| Jun 24, 2022 | BTIG | Marie Thibault | Buy | Maintains | $8.00 |
| Jan 18, 2022 | Guggenheim | Neutral | Downgrade | $N/A | |
| Jan 5, 2022 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $16.00 |
| Nov 10, 2021 | JMP Securities | David Turkaly | Market Outperform | Maintains | $18.00 |
| Apr 22, 2021 | Guggenheim | Buy | Initiates | $N/A | |
| Mar 23, 2021 | BTIG | Buy | Initiates | $N/A | |
| Feb 26, 2021 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jan 29, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Dec 3, 2020 | B. Riley FBR | Buy | Initiates | $N/A | |
| Dec 3, 2020 | B. Riley Securities | Buy | Initiates | $N/A | |
| Feb 5, 2020 | JMP Securities | Market Outperform | Initiates | $N/A | |
| Dec 20, 2019 | Dougherty & Co. | Buy | Initiates | $N/A |
iCAD Inc. (ICAD) Competitors
The following stocks are similar to Icad Inc based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
iCAD Inc. (ICAD) Financial Data
iCAD Inc. has a market capitalization of $106.31M with a P/E ratio of -18.4x. The company generates $19.53M in trailing twelve-month revenue with a -26.8% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of -23.2% and return on equity of -16.5%.
Valuation Metrics
Market Cap
$106.31M
Enterprise Value
$84.14M
P/E Ratio
-18.4x
PEG Ratio
0.5x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
-1.6%
Gross Margin
+85.9%
Operating Margin
-23.2%
Net Margin
-26.8%
EPS Growth
-1.6%
Financial Health
Cash/Price Ratio
+19.0%
Current Ratio
3.7x
Debt/Equity
1.0x
ROE
-16.5%
ROA
-9.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
iCAD Inc. (ICAD) Business Model
About iCAD Inc.
What They Do
Provides advanced cancer detection and treatment solutions.
Business Model
The company generates revenue by offering advanced image analysis, workflow solutions, and radiation therapy products primarily in the oncology and medical imaging sectors. Its business model focuses on integrating artificial intelligence to enhance diagnostic accuracy in cancer detection, particularly in digital mammography, while also delivering innovative radiation therapy solutions to improve patient outcomes.
Additional Information
iCAD is dedicated to advancing precision medicine and patient-specific treatment modalities, impacting a wide range of stakeholders, including healthcare providers and patients. The company's technologies are widely adopted in healthcare institutions, reflecting its commitment to enhancing the quality of cancer care through innovative solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
66
CEO
Ms. Dana R. Brown
Country
United States
IPO Year
1992
Website
www.icadmed.comiCAD Inc. (ICAD) Latest News & Analysis
Latest News
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of iCAD, Inc. to RadNet, Inc., where iCAD shareholders would receive 0.0677 shares of RadNet per iCAD share owned.
Why It Matters
The investigation into iCAD's sale to RadNet could indicate potential issues with the deal's valuation or process, affecting shareholder sentiment and stock prices for both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
iCAD, Inc. reported its financial and operational results for Q1 2025, focusing on AI-powered breast health solutions. Details of the performance were announced on May 13, 2025.
Why It Matters
iCAD's financial results indicate its performance and growth in the AI-driven healthcare sector, impacting investor sentiment and potential stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of iCAD, Inc. - ICAD
7 months ago
Quick Summary
Monteverde & Associates is investigating iCAD, Inc. (NASDAQ: ICAD) regarding its merger with RadNet, Inc., where iCAD shareholders will receive RadNet stock in exchange for their shares.
Why It Matters
The investigation into iCAD's merger with RadNet may impact stock valuations and shareholder sentiment, influencing investment decisions and market dynamics for both companies.
Source: PRNewsWire
Market Sentiment:
Neutral
ICAD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iCad, Inc. Is Fair to Shareholders
7 months ago
Quick Summary
Halper Sadeh LLC is investigating the fairness of iCAD, Inc.'s sale to RadNet, Inc. for 0.0677 shares of RadNet stock per iCAD share, urging shareholders to explore their legal rights.
Why It Matters
The investigation into iCAD's sale to RadNet raises concerns about shareholder value and fairness, potentially impacting stock performance and investor confidence in both companies.
Source: Business Wire
Market Sentiment:
Neutral
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
7 months ago
Quick Summary
iCAD, Inc. has appointed Mark Koeniguer as Chief Commercial Officer to drive global growth, focusing on AI-powered breast health solutions.
Why It Matters
Mark Koeniguer's appointment as CCO signals a strategic focus on global growth for iCAD, which could drive increased revenue and market share in the lucrative AI healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript
8 months ago
Quick Summary
iCAD, Inc. will hold its Q4 2024 earnings conference call on March 19, 2025, at 4:30 PM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides insights into iCAD's financial performance and strategic direction, crucial for assessing future growth potential and investment risks.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ICAD Stock
What is iCAD Inc.'s (ICAD) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, iCAD Inc. (ICAD) has a median price target of $3.75. The highest price target is $4.00 and the lowest is $3.50.
Is ICAD stock a good investment in 2026?
According to current analyst ratings, ICAD has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICAD stock?
Wall Street analysts predict ICAD stock could reach $3.75 in the next 12 months. This represents a -3.1% decrease from the current price of $3.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is iCAD Inc.'s business model?
The company generates revenue by offering advanced image analysis, workflow solutions, and radiation therapy products primarily in the oncology and medical imaging sectors. Its business model focuses on integrating artificial intelligence to enhance diagnostic accuracy in cancer detection, particularly in digital mammography, while also delivering innovative radiation therapy solutions to improve patient outcomes.
What is the highest forecasted price for ICAD iCAD Inc.?
The highest price target for ICAD is $4.00 from David Turkaly at JMP Securities, which represents a 3.4% increase from the current price of $3.87.
What is the lowest forecasted price for ICAD iCAD Inc.?
The lowest price target for ICAD is $3.50 from at , which represents a -9.6% decrease from the current price of $3.87.
What is the overall ICAD consensus from analysts for iCAD Inc.?
The overall analyst consensus for ICAD is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $3.75.
How accurate are ICAD stock price projections?
Stock price projections, including those for iCAD Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:01 PM UTC